New Guidance Targets Dangerous ‘Rhino Tranq’ Withdrawal

The American Society of Addiction Medicine (ASAM) has issued new clinical guidance on managing intoxication and potentially life-threatening complications from withdrawal associated with medetomidine, also known as “rhino tranq,” a veterinary sedative increasingly found in the illicit opioid supply. Although numerous substances have appeared in the illicit opioid supply over the years, “nothing has required this level of medical care and challenges for patients,” guideline co-author Jeanmarie Perrone, MD, director of the Center for Addiction Medicine and Policy at the University of Pennsylvania in Philadelphia, told Medscape Medical News . Medetomidine is a potent alpha-2 adrenergic receptor agonist approved as a veterinary sedative. It is 100-200 times more potent at the alpha-2 receptor than xylazine, another veterinary sedative found in the illicit opioid supply. First detected in the unregulated drug supply in 2021, medetomidine has since spread nationwide, with the highest prevalence in the Northeast and Midwest. In some mid-Atlantic opioid supplies, it has been detected in as many as 90% of samples. Acute medetomidine intoxication typically causes persistent sedation, bradycardia, and sometimes hypotension. Withdrawal, by contrast, can trigger tachycardia, agitation, tremor, intractable nausea and vomiting, and severe hypertension. In extreme cases, heart rates exceeding 170 beats/min and systolic blood pressures of 170-240 mm Hg have been reported. Rapid Onset of Severe Withdrawal Symptoms of severe withdrawal often emerge within 4-6 hours of last substance use, earlier than is typical with fentanyl withdrawal, and can progress rapidly over the following 24 hours. “That rapid progression can catch clinicians off guard,” M. Ross Lawson, MD, assistant professor of addiction medicine and emergency medicine at the University of Cincinnati (UC) College of Medicine in Cincinnati, who served as a field reviewer of the guidance, told Medscape Medical News . ASAM noted that the guidance is based largely on expert consensus, observational reports, and clinical experience because evidence remains insufficient to support a formal clinical practice guideline. For suspected overdose involving fentanyl contaminated with medetomidine, ASAM recommends administering naloxone in incremental doses until breathing is adequately restored. Naloxone does not reverse medetomidine’s effects, so sedation may persist even after respiratory function improves. Most patients with acute intoxication improve with supportive care, with 3-6 hours of postacute observation generally anticipated. For withdrawal, ASAM recommends early treatment with alpha-2 adrenergic agonists, particularly oral clonidine, with frequent reassessment and dose adjustments based on vital signs and clinical presentation. Guanfacine and tizanidine are additional options. Lawson noted that ASAM’s recommendations largely align with current practice and called the guidance a “much-needed resource,” particularly for clinicians in regions that have not yet experienced widespread medetomidine exposure. Frontline Physician Insights Cara Borelli, DO, an addiction medicine specialist at Yale School of Medicine in New Haven, Connecticut, who wasn’t involved in the guidance, emphasized the importance of initiating oral treatment early, before patients become unable to tolerate medications by mouth. “If the patient is already having profuse vomiting, it is often challenging to treat without requiring intravenous dexmedetomidine,” she told Medscape Medical News . Patients with severe withdrawal may require substantially higher doses of alpha-2 agonists than typically prescribed, making close monitoring essential. Perrone emphasized that treatment protocols, particularly alpha-2 agonist dosing, must be adapted to local patterns of exposure and dependence. She noted that in Philadelphia, clinicians have generally had to increase treatment doses as patient exposure to medetomidine has increased. Borelli added that dosing approaches will need to be adjusted based on a given center’s local patterns of exposure. For patients with uncontrolled vomiting despite combined antiemetic and alpha-2 agonist treatment, or those who develop severe tachycardia, hypertension, agitation, and encephalopathy despite treatment, ASAM recommends intravenous dexmedetomidine. Infusions are typically required for 24-72 hours, followed by a transition to oral alpha-2 agonists with gradual dose reductions. Because medetomidine is commonly combined with fentanyl, patients may experience both medetomidine and opioid withdrawal, which should be treated concurrently, ASAM advises. Richard Ryan, MD, professor of emergency medicine at UC College of Medicine, also welcomed the guidance and noted that significant gaps in care remain, even in regions where medetomidine is prevalent. “I truly believe we are undertreating patients experiencing medetomidine withdrawal,” said Ryan, who also wasn’t involved in developing the ASAM guidance. Maintain High Index of Suspicion Routine toxicology screens do not detect medetomidine, and advanced testing is generally unavailable for real-time clinical decision-making. Diagnosis therefore relies heavily on symptoms and knowledge of the local drug supply. Lawson advised maintaining a high index of suspicion when patients develop severe or persistent withdrawal symptoms despite aggressive treatment of opioid withdrawal. “Early recognition and frequent reassessment are critical, as these patients can deteriorate quickly,” he said. Ryan noted that medetomidine withdrawal can resemble alcohol, benzodiazepine, opioid, or precipitated withdrawal, making it difficult to identify the cause when standard treatments fail to control symptoms. He advised clinicians to obtain a “careful, nonjudgmental” substance use history and remain informed about local drug trends and adulterants. “Education of physicians and providers is the key,” Ryan said. “Bottom line, much education still needs to be done in how to properly take care of these patients.” ASAM will host an educational webinar on managing medetomidine intoxication and withdrawal on December 1 at 3:00 PM EST. The experts cited in this article had no relevant disclosures.